2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
This guideline cites 10 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2024
- Source
- Gornik HL, Aronow HD, et al. Circulation. 2024;149(24):e1313–e1410.doi 10.1161/CIR.0000000000001251
Where the ESC folds peripheral and aortic disease into a single 2024 document, the ACC/AHA guideline is confined to the lower limb and organises everything around four clinical subsets: asymptomatic disease, chronic symptomatic disease, chronic limb-threatening ischaemia and acute limb ischaemia. It endorses low-dose rivaroxaban plus aspirin after revascularisation on the strength of VOYAGER PAD, insists on structured exercise therapy before or alongside revascularisation for claudication, and — unlike its European counterpart — dedicates a formal recommendation set to foot care, wound prevention and multidisciplinary limb-preservation teams. The register's peripheral trials are grouped by question below.
Antithrombotic therapy3
- 2020VOYAGER PADCardiology · Vascular · Antithrombotic therapyIn 6,564 patients with peripheral artery disease after lower-extremity revascularisation, rivaroxaban 2.5 mg twice daily plus aspirin reduced acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke or cardiovascular death compared with aspirin alone.HR 0.8595% CI 0.76-0.96Read →
- 2017EUCLIDCardiology · Vascular · Antithrombotic therapyIn 13,885 patients with symptomatic peripheral artery disease, ticagrelor monotherapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with clopidogrel monotherapy.HR 1.0295% CI 0.92-1.13Read →
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
Chronic limb-threatening ischaemia: revascularisation2
- 2023BASIL-2Cardiology · Vascular · RevascularisationIn 345 patients with chronic limb-threatening ischaemia requiring infra-popliteal revascularisation, a vein-bypass-first strategy worsened amputation-free survival compared with a best-endovascular-treatment-first strategy.HR 1.3595% CI 1.02-1.80Read →
- 2022BEST-CLICardiology · Vascular · RevascularisationIn 1,830 patients with chronic limb-threatening ischaemia and infra-inguinal disease, surgical bypass reduced major adverse limb events or death compared with endovascular therapy, but only in those with an adequate single-segment great saphenous vein.Read →
Risk-factor modification & medical therapy3
- 2017FOURIERCardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
- 2015SPRINT CoreCardiology · HTN · BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
- 2000HOPECardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →
Diabetes & cardiometabolic therapy2
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2010CASPAR
Dual antiplatelet therapy after infra-inguinal bypass grafting — no overall benefit.
- 2012CLEVER
Supervised exercise matched or beat stenting for walking distance in aortoiliac claudication.
- 2005BASIL-1
Bypass versus angioplasty in severe limb ischaemia — the predecessor of BASIL-2.
- 2006CHARISMA
Clopidogrel plus aspirin versus aspirin alone — no benefit, the basis for single antiplatelet therapy in stable PAD.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.